About the Authors
- M. Cris Silva-Santisteban
-
Affiliations Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom, Division of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom
- Isaac M. Westwood
-
Affiliations Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom, Division of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom
- Kathy Boxall
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Nathan Brown
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Sam Peacock
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Craig McAndrew
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Elaine Barrie
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Meirion Richards
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Amin Mirza
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Antony W. Oliver
-
Current address: MRC Genome Damage and Stability Centre, University of Sussex, Brighton, Sussex, United Kingdom
Affiliation Division of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom
- Rosemary Burke
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Swen Hoelder
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Keith Jones
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- G. Wynne Aherne
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Julian Blagg
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Ian Collins
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Michelle D. Garrett
-
Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
- Rob L. M. van Montfort
-
* E-mail: Rob.vanMontfort@icr.ac.uk
Affiliations Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom, Division of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom
Competing Interests
The authors are current or former employees of The Institute of Cancer Research, which has a commercial interest in the development of checkpoint kinase inhibitors. The authors confirm that there are no patents relating to materials pertinent to this article. The authors’ commercial interest in the development of checkpoint kinase inhibitors does not alter their adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MCSS IMW KB NB CM EB AM MDG IC RLMvM. Performed the experiments: MCSS IMW KB NB SP CM EB MR AM. Analyzed the data: MCSS IMW KB SP MR AWO RB SH KJ GWA JB IC MDG RLMvM. Contributed reagents/materials/analysis tools: AWO IC SH KJ JB RB GWA RLMvM. Wrote the paper: MCSS IMW RLMvM.